WO1993013068A1 - Tricyclic compound and medicine containing the same - Google Patents
Tricyclic compound and medicine containing the same Download PDFInfo
- Publication number
- WO1993013068A1 WO1993013068A1 PCT/JP1992/001640 JP9201640W WO9313068A1 WO 1993013068 A1 WO1993013068 A1 WO 1993013068A1 JP 9201640 W JP9201640 W JP 9201640W WO 9313068 A1 WO9313068 A1 WO 9313068A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- ylidene
- group
- same
- ethoxy
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 title abstract description 25
- 230000001387 anti-histamine Effects 0.000 claims abstract description 12
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 12
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 9
- 230000001088 anti-asthma Effects 0.000 claims abstract description 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 239000000924 antiasthmatic agent Substances 0.000 claims abstract description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- YIELSLPTXCVFNL-UHFFFAOYSA-N 1-benzhydryloxypiperidine Chemical class C1CCCCN1OC(C=1C=CC=CC=1)C1=CC=CC=C1 YIELSLPTXCVFNL-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract description 8
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000006454 hepatitis Diseases 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 201000008383 nephritis Diseases 0.000 abstract description 2
- 208000023504 respiratory system disease Diseases 0.000 abstract description 2
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 229930192474 thiophene Chemical group 0.000 abstract 1
- -1 ethoxyl Chemical group 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical group CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 1
- QMYGFTJCQFEDST-UHFFFAOYSA-N 3-methoxybutyl acetate Chemical group COC(C)CCOC(C)=O QMYGFTJCQFEDST-UHFFFAOYSA-N 0.000 description 1
- INPJSDMJYRCDGA-UHFFFAOYSA-N 4-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)piperidine Chemical compound C1CNCCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 INPJSDMJYRCDGA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- Tricyclic compounds and pharmaceuticals containing them Tricyclic compounds and pharmaceuticals containing them
- the present invention relates to a novel tricyclic compound exhibiting strong antihistamine action and having high safety, and an antiallergic agent such as an antiasthmatic drug and an antihistamine containing the same.
- Japanese Unexamined Patent Publication No. 2-503909, Japanese Unexamined Patent Publication No. 3-128354, and Japanese Unexamined Patent Publication No. 3-504012 disclose compounds having antiallergic activity, antihistamine effect, etc. However, these compounds do not yet fully satisfy both safety and efficacy.
- the present invention provides a compound represented by the general formula (I):
- R represents a hydrogen atom or a halogen atom
- X represents a group CH 2 CH 2 —
- One CH CH- or a single CH 2 - CO- indicates
- A is a benzene ring, indicates Chiofen ring or Pyridine ring
- B is a hydroxyl group, a lower alkoxyl group or a group - indicates
- NH m is 2-5 Indicates an integer.
- the present invention has excellent antihistamine action such as anti-asthma action, anti-allergic action, etc. and high safety. Therefore, it is a therapeutic agent for various allergic diseases, for example, treatment for anti-inflammatory nephritis, hepatitis and knee inflammation. And preventive and / or cure of respiratory diseases and antiasthmatics.
- examples of the lower alkoxyl group represented by B include alkoxyl groups having 1 to 4 carbon atoms or 1 or 2 odors, and methoxyl, ethoxyl, propoxyl, butoxyl and isomers thereof are preferable.
- examples of the halogen atom for R include m, fluorine and iodine atoms.
- the compound of the present invention can be used as a pharmacologically acceptable salt.
- a salt include a fiber salt, a nitrate, a fiber salt, an acetate, a maleate, a fumarate, a oxalate, and a quinate.
- Acid addition salts such as acid salts, hydrobromides, succinates, sfflefamates, mandelates, malonates, phosphates, etc., or sodium salts, potassium salts, lithium salts, calcium salts, etc. Salt s1 ⁇ 2 salt.
- Compound (I) of the present invention can be prepared, for example, according to the following method.
- R, X, A and m have the same meaning as described above, B 1 represents a lower alkyl group, and Z represents a halogen atom.
- the above-mentioned core is preferably carried out in a solvent that does not affect the reaction.
- a solvent include esters such as methyl acetate and ethyl acetate; ethers such as getyl ether, diisopropyl ether, tetrahydrofuran and dioxane; ketones such as acetone and methyl ethyl ketone; acetonitrile and dimethyl Sulfoxide, dimethylformamide and the like; halogenated hydrocarbons such as dichloromethane and chloroform; and aromatic hydrogen such as benzene, toluene and xylene. These can be used alone or as a mixture.
- ⁇ may be changed according to the raw material used ⁇ ), and it is usually advantageous to select from 0 ° C to reflux temperature under normal pressure.
- potassium carbonate, sodium carbonate, sodium carbonate examples thereof include carbonates such as hydrogen carbonate and the like, and organic groups such as triethylamine, diisopropylamine, 1,8-diazabicyclo [5.4.0] -7-undecene (DBU).
- DBU 1,8-diazabicyclo [5.4.0] -7-undecene
- This condensation reaction is preferably carried out according to a known method without affecting the reaction.
- solvents include, for example, esters such as methyl acetate and ethyl acetate; amides such as dimethylformamide and getylformamide; ethers such as getyl ether, diisopropyl ether, tetrahydrofuran and dioxane; acetonitrile; Dimethyl sulfoxide, etc .; dichloromethane, chloropho Halogenated hydrocarbons such as lume; aromatic hydrocarbons such as benzene and tolues xylene; These can be used in insects or mixed.
- condensing agent examples include carbodiimide derivatives such as N, N'-dicyclohexylcarbodiimide and 1, ⁇ -carbonyldiimidazole.
- the thus-obtained compound (I) of the present invention can be formulated into a preparation for oral administration or a preparation for parenteral administration by combining a pharmaceutically acceptable auxiliary.
- Formulations for oral administration include the above compounds in suitable additives, for example, excipients such as mannitol, corn starch, crystalline cellulose; binders such as cellulose-derived gum arabic and gelatin; disintegration of carboxymethylcellulose calcium and the like.
- Agents Powders, powders, granules, and capsules can be prepared by combining them with lubricants such as talc and magnesium stearate appropriately. Further, these solid preparations are made enteric-soluble by using a coating base such as hydroxypropyl methylcellulose phthalate, hydroxybutyl propylmethylcellulose acetate succinate, cellulose acetate phthalate, and methacrylate copolymer.
- a coating base such as hydroxypropyl methylcellulose phthalate, hydroxybutyl propylmethylcellulose acetate succinate, cellulose acetate phthalate, and methacrylate copolymer.
- Liquid preparations for oral administration include emulsions, solutions, suspensions, syrup U, elixirs, etc., and commonly used inert diluents such as purified M, ethanol, etc. be able to.
- This omega-substance may contain, in addition to the inert diluent, adjuvants such as wetting agents and emollients, sweetening agents, flavoring agents, fragrances, preservatives and the like.
- adjuvants such as wetting agents and emollients, sweetening agents, flavoring agents, fragrances, preservatives and the like.
- it can also be an aerosol formulated by a known method.
- a liquid preparation can be prepared by combining, for example, water, ethanol, glycerin, a conventional surfactant and the like.
- it can be an inhalant, a topical solution, an eye drop, a nasal drop, or a coating such as an ointment formulated by a known method.
- the dose of the compound (I) of the present invention varies depending on age, body weight, symptom, therapeutic effect, administration method and administration period, but is usually 1 to 500 ⁇ ⁇ days, preferably 5 to 50ag / day.
- Administer orally 1 to 3 times a day or parenteral once to several times a day in the range of 0.1 to 500 ng Administer. ⁇
- the ileum was removed from male Hartley guinea pigs (body weight 300-600 g) and suspended in a Magnus bath (30.C, under aeration) filled with lOmfl Tyrode's solution at an initial load of 0.5 g.
- Anti-BP0-BGG serum diluted 20-fold with a physiological diet was administered at a rate of 1 / kg to the hind limb vein of 4 guinea pigs per group to passively sensitize.
- PSA was induced by intravenously administering 0.5 ng / BP0-BGG at a rate of lmfl / kg.
- the compound obtained in Example 5 was orally administered to guinea pigs fasted on the previous day at a rate of 4 ng / kg one hour before the antigen administration.
- the general symptoms of guinea pigs were observed, and the best response was determined from the mortality rate. As a result, the highest expression level was 1.0 ng / kg.
- mice Four to five-week-old ICR mice (Charles Lipper) were used as 10 mice per group. After the compound obtained in each Example became cloudy with 5% gum arabic, each compound was orally administered at a dose of 1000 mg / kg, and observation was performed for 7 days. As a result, no deaths due to the toxicity of the compound of the present invention were observed. Difficult case
- Example 4 The compounds of Examples 4 to 15 shown in Tables 3 to 5 were obtained according to the methods of mi to 3. Each chemical name is as follows. In the table, A, B, R, m and X represent symbols in the compound (I) of the present invention. In addition, in the column of the X group in the table, it represents a bond with the A ring. ⁇ Example 4
- the above components are mixed uniformly, and a 200% aqueous solution of 7.5% hydroxypropylcellulose is added, and the mixture is granulated by an extrusion granulator using a screen with a diameter of 0.5, immediately rounded with a marmellaizer, and dried to obtain granules. did.
- the dry granules were coated with 1.9 kg of the following film coating solution using a fluidized bed machine to obtain enteric coated granules.
- the tablet was spray-coated with a coating solution having the following composition to give a coating of 100 ng per tablet, thereby obtaining an enteric film coating ⁇ 0.
- the aerosol was prepared by the usual method.
- the compound of the present invention exhibits strong antihistamine activity and high safety. It is useful as a prophylactic and / or curative drug and as an anti-asthmatic drug.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A tricyclic compound represented by general (I), a salt thereof, and an antihistaminic and an antiallergic containing the same as the active ingredient wherein R represents hydrogen or halogen; X represents -CH2CH2-, -CH=CH- or -CH2-CO-; A represents benzene, thiophene or pyridine; B represents hydroxy, lower alkoxy or (α); and m represents an integer of 2 to 5. The compound has a potent antihistaminic activity and a high safety, and is hence useful for treating various allergic diseases including inflammation, nephritis, hepatitis, pancreatitis, etc., for preventing and/or treating respiratory system diseases, and as an antiasthmatic.
Description
明 細 書 Specification
三環系化合物及びこれを含有する医薬 技術分野 Tricyclic compounds and pharmaceuticals containing them
本発明は、 強い抗ヒスタミン作用を示し、 かつ安全性も高い新規な三環系化合 物並びにこれを含有する抗喘息薬等の抗アレルギー剤及び抗ヒス夕ミン剤に関す る。 背景 The present invention relates to a novel tricyclic compound exhibiting strong antihistamine action and having high safety, and an antiallergic agent such as an antiasthmatic drug and an antihistamine containing the same. Background
«、 数多くの Ξ環系化^ lが合成され、 それらの抗喘息作用等の抗アレルギ ~f乍用及び抗ヒスタミン作用などが検討されているが、 充分な効果を有し、 かつ 安全性の高い化^は知られていない。 «Many Ξ-rings have been synthesized, and their anti-allergic and anti-histamine actions such as anti-asthmatic action have been studied, but they have sufficient effects and safety. The rise is not known.
例えば、 特表平 2-503909号公報、 特開平 3-128354号公報、 特表平 3-504012号公 報などに抗アレルギ ~f乍用、 抗ヒス夕ミン作用などを有する化^が開示されて いるが、 それらの化合物は未だ安全性と有効性の両者を十分に満足するものでは ない。 For example, Japanese Unexamined Patent Publication No. 2-503909, Japanese Unexamined Patent Publication No. 3-128354, and Japanese Unexamined Patent Publication No. 3-504012 disclose compounds having antiallergic activity, antihistamine effect, etc. However, these compounds do not yet fully satisfy both safety and efficacy.
そこで、 本発明者らは、 より優れた抗喘息作用等の抗アレルギ~ 用及び抗ヒ ス夕ミン作用を併せ持ち、 かつ安全性の高い化合物を創製すべく鋭意研究を行い、 本発明を完成するに至った。 発明の開示 Therefore, the present inventors have conducted intensive studies to create a compound that has both an anti-allergic effect such as an anti-asthmatic effect and an anti-histamine effect and is highly safe, and completes the present invention. Reached. Disclosure of the invention
本発明は、 一般式 ( I ) The present invention provides a compound represented by the general formula (I):
(式中、 Rは水素原子又はハロゲン原子を示し、 Xは基一 CH2CH2—,
一 CH=CH—又は一 CH2— CO—を示し、 Aはベンゼン環、 チォフェン 環又はビリジン環を示し、 Bはヒドロキシル基、 低級アルコキシル基又は 基 -NH , を示し、 mは 2〜5の整数を示す。 ) (Wherein, R represents a hydrogen atom or a halogen atom, and X represents a group CH 2 CH 2 —, One CH = CH- or a single CH 2 - CO- indicates, A is a benzene ring, indicates Chiofen ring or Pyridine ring, B is a hydroxyl group, a lower alkoxyl group or a group - indicates, NH, m is 2-5 Indicates an integer. )
H H
で表される三環系化^/及びその塩並びにこれを有効成分とする抗ヒス夕ミン剤 並びに抗ァレノレギ Uに係るものである。 And a salt thereof, and an anti-histamine compound containing the tricyclic compound as an active ingredient and anti-arenoregi U.
本発明化 は)は、優れた抗喘息作用等の抗ヒスタミン作用、 抗アレルギー 作用を有し、 かつ安全性も高いので、各種アレルギ 疾患の治療剤、例えば抗 炎 腎炎、 肝炎及び膝炎の治療剤、 呼吸 患の予防及び/又は治 及び 抗喘息薬として有用である。 発明を するための最良の形態 The present invention has excellent antihistamine action such as anti-asthma action, anti-allergic action, etc. and high safety. Therefore, it is a therapeutic agent for various allergic diseases, for example, treatment for anti-inflammatory nephritis, hepatitis and knee inflammation. And preventive and / or cure of respiratory diseases and antiasthmatics. BEST MODE FOR CARRYING OUT THE INVENTION
式(I)において、 Bの低級アルコキシル基としては、 炭素数 1〜4の麵 又は分 ¾1臭のアルコキシル基が挙げられ、 メトキシル、 エトキシル、 プロボキシ ル、 ブトキシル基及びその異性体が好ましい。 また、 Rのハロゲン原子としては、 m, フッ素及びヨウ素原子が挙げられる。 In the formula (I), examples of the lower alkoxyl group represented by B include alkoxyl groups having 1 to 4 carbon atoms or 1 or 2 odors, and methoxyl, ethoxyl, propoxyl, butoxyl and isomers thereof are preferable. Examples of the halogen atom for R include m, fluorine and iodine atoms.
本発明の化合物は薬理学的に許容される塩として用いることができ、 このよう な塩としては、 例えば繊塩、硝酸塩、纖塩、酢酸塩、 マレイン酸塩、 フマル ^, シユウ酸塩、 クェン酸塩、 臭化水素酸塩、 コハク酸塩、 スフレファミン酸塩、 マンデル酸塩、 マロン酸塩、 リン酸塩等の酸付加塩、 又はナトリウム塩、 力リウ ム塩、 リチウム塩、 カルシウム塩等の塩 s½塩を挙げることができる。 The compound of the present invention can be used as a pharmacologically acceptable salt. Examples of such a salt include a fiber salt, a nitrate, a fiber salt, an acetate, a maleate, a fumarate, a oxalate, and a quinate. Acid addition salts such as acid salts, hydrobromides, succinates, sfflefamates, mandelates, malonates, phosphates, etc., or sodium salts, potassium salts, lithium salts, calcium salts, etc. Salt s½ salt.
本発明の化合物( I )は、例えば以下に示す方法に従つて^ tすることができる。
Compound (I) of the present invention can be prepared, for example, according to the following method.
(式中、 R、 X、 A及び mは前記と同意義を有し、 B1は低級アルキル基を示し、 Zはハロゲン原子を示す。 ) (Wherein, R, X, A and m have the same meaning as described above, B 1 represents a lower alkyl group, and Z represents a halogen atom.)
すなわち、 一般式 (II)で表されるピペリジン誘導体と一般式 (ffl)で表されるサ リチル酸誘導体を塩基の存在下で反応させることにより、 一般式 ( I )において B が低級アルコキシル基であるエステル誘導体 (la)が される。 That is, by reacting a piperidine derivative represented by the general formula (II) with a salicylic acid derivative represented by the general formula (ffl) in the presence of a base, B in the general formula (I) is a lower alkoxyl group. An ester derivative (la) is synthesized.
上記の 芯は、 反応に影響を及ぼさない溶媒中で行うことが好ましい。 このよ うな溶媒としては、 例えば酢酸メチル、 酢酸ェチル等のエステル類;ジェチルェ 一テル、 ジイソプロビルエーテル、 テトラヒドロフラン、 ジォキサン等のエーテ ル類;アセトン、 メチルェチルケトン等のケトン類;ァセトニトリル、 ジメチル スルホキシド、 ジメチルホルムアミド等;ジクロロメタン、 クロ口ホルム等のハ ロゲン化炭化水素;ベンゼン、 トルエン、 キシレン等の芳香 匕水素などが挙 げられる。 これらは単独で又は混合して使用することができる。 The above-mentioned core is preferably carried out in a solvent that does not affect the reaction. Examples of such a solvent include esters such as methyl acetate and ethyl acetate; ethers such as getyl ether, diisopropyl ether, tetrahydrofuran and dioxane; ketones such as acetone and methyl ethyl ketone; acetonitrile and dimethyl Sulfoxide, dimethylformamide and the like; halogenated hydrocarbons such as dichloromethane and chloroform; and aromatic hydrogen such as benzene, toluene and xylene. These can be used alone or as a mixture.
继は使用する原料化^)に応じて変化させればよく、 通常は常圧下、 0 °Cないし還流温度の範囲で選ぶのが有利である。 继 may be changed according to the raw material used ^), and it is usually advantageous to select from 0 ° C to reflux temperature under normal pressure.
としては、 例えば炭酸カリウム、 炭酸ナトリウム、 炭^素ナトリウム、
炭酸水素力リゥム等の炭酸塩又はトリェチルァミン、 ジイソプロビルァミン、 1, 8-ジァザビシクロ [5. 4. 0] -7-ゥンデセン(DBU)等の有^ 基類が挙げられる。 次に、下阪応式に示すように、 I3 によって生成されるエステル誘導体 (la)を通常用いられる加水分解 に付することによつて対応するカルボン酸誘 導体 (lb)が得ら さらに、 このカルボン酸誘導体 (lb)を 5-ァミノ- 1H-テトラゾ ールと縮合させることにより、 一般式( I )において Bが 5-1H-テトラゾリルァミ ノ基である本発明化^ ¾ (Ic)に導くことができる。 For example, potassium carbonate, sodium carbonate, sodium carbonate, Examples thereof include carbonates such as hydrogen carbonate and the like, and organic groups such as triethylamine, diisopropylamine, 1,8-diazabicyclo [5.4.0] -7-undecene (DBU). Next, as shown in the Shimosaka O formula, the corresponding carboxylic acid derivative (lb) was obtained by subjecting the ester derivative (la) generated by I3 to hydrolysis that is usually used. The condensation of the carboxylic acid derivative (lb) with 5-amino-1H-tetrazole leads to the present invention (Ic) in which B in the general formula (I) is a 5-1H-tetrazolylamino group. Can be.
(式中、 R、 X、 A及び mは前記と同意義を有する。 ) (Wherein, R, X, A and m have the same meaning as described above.)
この縮合反応は公知の方法に準じ、反応に影響を及ぼさない 中で行うこと が好ましい。 このような溶媒としては、例えば酢酸メチル、酢酸ェチル等のエス テル類;ジメチルホルムアミド、 ジェチルホルムアミド等のアミド類;ジェチル エーテル、 ジイソプロビルエーテリレ、 テトラヒドロフラン、 ジォキサン等のエー テル類;ァセトニトリル、 ジメチルスルホキシド等;ジクロロメタン、 クロロホ
ルム等のハロゲン化炭化水素;ベンゼン、 トルエス キシレン等の芳香族炭化水 素などが挙げられる。 これらは ?虫で又は混合して使用することができる。 This condensation reaction is preferably carried out according to a known method without affecting the reaction. Such solvents include, for example, esters such as methyl acetate and ethyl acetate; amides such as dimethylformamide and getylformamide; ethers such as getyl ether, diisopropyl ether, tetrahydrofuran and dioxane; acetonitrile; Dimethyl sulfoxide, etc .; dichloromethane, chloropho Halogenated hydrocarbons such as lume; aromatic hydrocarbons such as benzene and tolues xylene; These can be used in insects or mixed.
縮合剤としては、 N, N' -ジシクロへキシルカルボジィミド、 1, Γ -カルボニルジ イミダゾール等のカルポジィミド誘導体などが挙げられる。 Examples of the condensing agent include carbodiimide derivatives such as N, N'-dicyclohexylcarbodiimide and 1, Γ-carbonyldiimidazole.
は、 使用する原料化^/に応じて変ィ匕させればよく、 通常は常圧下、 0でないし還流温度の範囲で選ぶのが有利である。 May be changed according to the raw material used, and it is usually advantageous to select under normal pressure a value other than 0 or a reflux temperature.
このようにして得られた本発明の化合物( I )は、 ¾上許容される補助剤を配 合して、 経口投与用製剤又は非経口投与用製剤とすることができる。 The thus-obtained compound (I) of the present invention can be formulated into a preparation for oral administration or a preparation for parenteral administration by combining a pharmaceutically acceptable auxiliary.
経口投与用の製剤としては、 上記化合物を適当な添加剤、 例えば 、 マンニ ヅト、 トウモロコシデンプン、 結晶セルロース等の賦形剤;セルロース誘導 アラビアゴム、 ゼラチン等の結合剤、 カルボキシメチルセルロースカルシウム等 の崩壊剤;タルク、 ステアリン酸マグネシウム等の滑沢剤等々と適当に組み合せ ることにより餘剤、 散剤、 顆粒剤、 カプセル剤とすることができる。 また、 これ らの固型製剤をヒドロキシプロビルメチルセルロースフタレート、 ヒドロキシブ 口ピルメチルセルロースアセテートサクシネート、 セルロースアセテートフタレ ート、 メタァクリレートコーポリマーなどの被覆用基剤を用いて腸溶性 とす ることができる。 Formulations for oral administration include the above compounds in suitable additives, for example, excipients such as mannitol, corn starch, crystalline cellulose; binders such as cellulose-derived gum arabic and gelatin; disintegration of carboxymethylcellulose calcium and the like. Agents: Powders, powders, granules, and capsules can be prepared by combining them with lubricants such as talc and magnesium stearate appropriately. Further, these solid preparations are made enteric-soluble by using a coating base such as hydroxypropyl methylcellulose phthalate, hydroxybutyl propylmethylcellulose acetate succinate, cellulose acetate phthalate, and methacrylate copolymer. Can be
絰ロ投与用の液剤としては、 乳濁剤、 溶液剤、 懸濁剤、 シロヅ U、 エリキシ ル剤等を含み、 一般的に用いられる不活性な希!^、 例えば精 M、 エタノール 等を含むことができる。 この ω物は不活性な希釈剤以外に湿潤剤、 想濁剤のよ うな補助剤、 甘味剤、 風味剤、 芳香剤、 防腐剤等を含有していてもよい。 その他、 公知の方法により処方されるエアゾール剤とすることもできる。 Liquid preparations for oral administration include emulsions, solutions, suspensions, syrup U, elixirs, etc., and commonly used inert diluents such as purified M, ethanol, etc. be able to. This omega-substance may contain, in addition to the inert diluent, adjuvants such as wetting agents and emollients, sweetening agents, flavoring agents, fragrances, preservatives and the like. In addition, it can also be an aerosol formulated by a known method.
非経口投与用の製剤としては、 例えば水、 エタノール、 グリセリン、 慣用の界 面活性剤等を組み合せることにより ¾*ί用液剤とすることができる。 さらに、 公 知の方法により処方される吸入剤、 外用液剤、 点眼剤、 点鼻剤、 軟膏のような塗 布剤等とすることができる。 As a preparation for parenteral administration, a liquid preparation can be prepared by combining, for example, water, ethanol, glycerin, a conventional surfactant and the like. In addition, it can be an inhalant, a topical solution, an eye drop, a nasal drop, or a coating such as an ointment formulated by a known method.
本発明の化合物 ( I )の投与量は、 年齢、 体重、 症状、 治療効果、 投与方法、 投 与期間により異なるが、 通常、 1〜500π^日、 好ましくは 5〜50ag/日の範囲 で 1日 1〜3回経口投与するか、 又は 0. l〜500ngの範囲で 1日 1回〜数回非経口
投与する。 舰 The dose of the compound (I) of the present invention varies depending on age, body weight, symptom, therapeutic effect, administration method and administration period, but is usually 1 to 500π ^ days, preferably 5 to 50ag / day. Administer orally 1 to 3 times a day or parenteral once to several times a day in the range of 0.1 to 500 ng Administer.舰
〈抗ヒスタミン ί乍用〉 <For antihistamines>
雄性 Hartley系モルモヅト (体重 300〜600g) より回腸を摘出し、 lOmflの Tyrode 液を満たしたマグヌス槽(30。C、通気下)中に初期負荷 0. 5gで懸垂した。試験化 合物をヒスタミン (3 X10-7モル)添加前 3分間処置し、 ヒスタミンによる摘出 回腸の の抑制作用を、 腿力変化の測定により検討し、抗ヒスタミ ン作用 (50%抑制濃度: IC50値) を求めた。 この結果を表 1に示す。The ileum was removed from male Hartley guinea pigs (body weight 300-600 g) and suspended in a Magnus bath (30.C, under aeration) filled with lOmfl Tyrode's solution at an initial load of 0.5 g. The test of compound treated histamine (3 X10- 7 mol) added before 3 minutes, the inhibitory effect of the isolated ileum by histamine was examined by measurement of the thigh force change, antihistamine down effect (50% inhibitory concentration: IC 50 values). Table 1 shows the results.
: 1 抗ヒスタミン作用 : 1 Antihistamine action
〈抗アレルギー作用〉 <Anti-allergic action>
雄性 SD系ラヅト (体重 150〜250g) の背部を予め毛刈し、生理:^及び生理 ^ lで適当な濃度に希釈した抗 DNP-As (Dinitrophenyl conjugated Ascaris) IgE血清 O. lmflを背部皮内に注射し、 受動的に感作した。 48時間後に 2. 5ng の DNP-BSA (Dinitrophenyl conjugated Bovine Serum Albumin) を ^ fO. 5%Evans Blue生理食^ K lmfiを静脈内投与した。 30分後に ¾«C死せしめ背部皮膚の青斑 部位を皮革用パンチにて打ち抜き、 原田らの方法(アレルギー, 15, 1-7, (1966) ) に従い漏出色素量を測定した。 受動感作皮痏アナフィラキシー (PCA) による漏 出色素量は、 PCA部位の漏出色素量から生理:^ *投与部位の漏出色素量を差し 引いて求めた。試験化合物は 5 %アラビアゴム又は 0. 5%メチルセルロースに想 濁し、 lOmg/4 / kgを娜投与 1時間前に経口投与した。纖化^/の効力は漏 出色素量の抑制率(抗アレルギ" ·{乍用) で判定した。 この結果を表 2に示す。
表 2 抗アレルギー作用 The back of a male SD rat (body weight 150-250g) was shaved beforehand, and anti-DNP-As (Dinitrophenyl conjugated Ascaris) IgE serum O. lmfl diluted to appropriate concentrations with physiology: ^ and physiology ^ l intradermally into the back And sensitized passively. Forty-eight hours later, 2.5 ng of DNP-BSA (Dinitrophenyl conjugated Bovine Serum Albumin) was administered intravenously with ^ fO. 5% Evans Blue physiological diet ^ K lmfi. After 30 minutes, the blue spots on the back skin were punched out with a punch for leather, and the amount of leaked pigment was measured according to the method of Harada et al. (Allergy, 15, 1-7, (1966)). The amount of pigment leaked by passive sensitization skin anaphylaxis (PCA) was calculated by subtracting the amount of pigment leaked at the site of administration: ^ * from the amount of pigment leaked at the PCA site. The test compound was suspended in 5% gum arabic or 0.5% methylcellulose and orally administered lOmg / 4 / kg 1 hour before administration of Na. The efficacy of fiberized ^ / was determined by the rate of suppression of the amount of leaked dye (anti-allergic) .The results are shown in Table 2. Table 2 Antiallergic effects
〈抗喘息作用〉 <Anti-asthmatic effect>
生理食 ί¾を用いて 20倍に希釈した抗 BP0-BGG血清を、 1 /kgの割合で 1群 4 匹のモルモヅトの後肢静脈に投与し、 受動的に感作した。 48時間後に 0. 5ng / の BP0-BGGを l mfl/kgの割合で静脈内投与して PSAを惹起した。実施例 5で得られた 化合物を前日に絶食としたモルモヅトに抗原投与の 1時間前に 4ng/kgの割合で 経口投与した。 モルモットの一般症状を観察し、 死亡率から最 効発 ¾1を求 めた。 この結果、 最«¾発現量は 1. 0ng/kgであった。 Anti-BP0-BGG serum diluted 20-fold with a physiological diet was administered at a rate of 1 / kg to the hind limb vein of 4 guinea pigs per group to passively sensitize. After 48 hours, PSA was induced by intravenously administering 0.5 ng / BP0-BGG at a rate of lmfl / kg. The compound obtained in Example 5 was orally administered to guinea pigs fasted on the previous day at a rate of 4 ng / kg one hour before the antigen administration. The general symptoms of guinea pigs were observed, and the best response was determined from the mortality rate. As a result, the highest expression level was 1.0 ng / kg.
〈毒性難〉 <Toxic difficulty>
4〜5週齢の ICR系マウス (チヤ一ルス ·リパー社) を 1群 10匹として用いた。 各実施例で得られた化合物を 5 %アラビアゴムに懇濁した後、 それそれ 1000 mg/kgの用量にて経口投与し、 7日間にわたり観察を行った。その結果、 本発明 の化合物の毒性に起因した死亡例は認められなかった。 難例 Four to five-week-old ICR mice (Charles Lipper) were used as 10 mice per group. After the compound obtained in each Example became cloudy with 5% gum arabic, each compound was orally administered at a dose of 1000 mg / kg, and observation was performed for 7 days. As a result, no deaths due to the toxicity of the compound of the present invention were observed. Difficult case
以下、 »例により本発明をさらに具体的に説明するが、 本発明はこれらによ り限定されるものではない。 Hereinafter, the present invention will be described more specifically with reference to Examples, but the present invention is not limited thereto.
贿例 1 贿 Example 1
2- [2- [4- (5H-ジベンゾ [a, d]シクロヘプテン- 5-ィリデン ) -1-ビペリジニル]ェ トキシ]ベンゾィヅクァシヅドメチルエステル
2- [2- [4- (5H-dibenzo [a, d] cycloheptene-5-ylidene) -1-biperidinyl] ethoxy] benzodiacid methyl ester
4- (5H-ジベンゾ [a,d]シクロへブテン- 5-イリデン)ピぺリジン 2.73g (10廳 ol) をアセトン 50υώに溶かし、 2- (2-ブロモエトキシ)ベンゾィヅクァシヅドメチル エステル 3. Ig (12腿 ol)及び炭酸カリウム 1.66g (12薩 ol) を加え、 3時間加熱 »した。 ίδ液を永水中にあけ酢酸ェチルにて抽出し、 I ^食 ¾で洗浄後、 «c硫酸マグネシウムにて した。霞留去後、 得られた残留物をシリカゲル カラムクロマトグラフィー(群酸ェチル: n-へキサン = 1: 1) にて精製し、 標
収率 87%。 Dissolve 2.73 g (10 cafe ol) of 4- (5H-dibenzo [a, d] cycloheptene-5-ylidene) piperidine in 50 ml of acetone and give 2- (2-bromoethoxy) benzodiacid methyl. Ester 3. Ig (12 t ol) and potassium carbonate 1.66 g (12 t ol) were added and heated for 3 hours. The ίδ solution was poured into permanent water, extracted with ethyl acetate, washed with I ^ diet, and washed with magnesium sulfate. After evaporation of the haze, the obtained residue was purified by silica gel column chromatography (ethyl acetate: n-hexane = 1: 1), 87% yield.
(分解点) : 144〜U5。C (フマール酸塩) (Decomposition point): 144 to U5. C (Fumarate)
MS (i/z) : 451 (M MS (i / z): 451 (M
IRfn joDcni-1 : 1720, 1690 IRfn joDcni- 1 : 1720, 1690
腿 (DMSO-de) δ: (フマール艦) L 99-2.05 (2Η, ι), 2.30-2.50 (4H, m) , Thigh (DMSO-de) δ: (Humal) L 99-2.05 (2Η, ι), 2.30-2.50 (4H, m),
2.70-2.90 (2H,m), 2.76 (2H, t) , 3.72(3H,s), 4.16(2H,t), 6.61(2H,s), 6.97(2H,s), 7.00-7.63 (12H, m) 2.70-2.90 (2H, m), 2.76 (2H, t), 3.72 (3H, s), 4.16 (2H, t), 6.61 (2H, s), 6.97 (2H, s), 7.00-7.63 (12H, m)
2- [2- [4- (5H-ジベンゾ [a, d]シクロへブテン- 5-ィリデン) -卜ピペリジニル〗ェ トキシ]ペンゾィックァシッド 2- [2- [4- (5H-dibenzo [a, d] cycloheptene-5-ylidene) -topiperidinylethoxy] penzoic acid
mm 1で得られた 2- [2- [4- (SH-ジベンゾ [a, d]シクロヘプテン- 5-ィリデン) - 2- [2- [4- (SH-dibenzo [a, d] cycloheptene-5-ylidene) obtained in mm 1
1-ピぺリジニル]ェトキシ]ベンゾィヅクァシヅドメチルエステル ·フマール酸塩 l.Og (1.76匪 ol) をエタノール 10mlに溶解し、 水酸化カリウム 0.5gを加えて、 70でで 2時間撹拌した。冷後、 水を加え、 さらに酢酸を加えて pH6とし、 酢酸ェ チルにて抽出、 S¾食駄で洗浄後、 無水碰マグネシウムにて乾燥した。職 留去後、 得られた残留物をシリカゲルカラムクロマトグラフィー(クロ口ホルム :メタノール =20 : 1)にて精製し、標記化^ 640mgを得た。収率 83%。 Dissolve 1-piridinyl] ethoxy] benzodiacid methyl ester fumarate l.Og (1.76 marl) in 10 ml of ethanol, add 0.5 g of potassium hydroxide and stir at 70 for 2 hours did. After cooling, water was added, and acetic acid was further added to adjust the pH to 6, and the mixture was extracted with ethyl acetate, washed with S¾ waste, and dried over anhydrous magnesium. After evaporation, the obtained residue was purified by silica gel column chromatography (chloroform: methanol = 20: 1) to obtain 640640 mg of the title. Yield 83%.
アモルファス Amorphous
MS (m/z) : 437 (M+) MS (m / z): 437 (M +)
IR(nujol) ci"1: 1711 IR (nujol) ci " 1 : 1711
腿 (CDCls) 6: 2.06-2.15 (2H, m), 2.20-2.30 (2H, m) , 2.45-2.56 (2Η, m) , Thigh (CDCls) 6: 2.06-2.15 (2H, m), 2.20-2.30 (2H, m), 2.45-2.56 (2Η, m),
2.68 (2H, t), 2.66-2.76 (2Η,ι), 4.32 (2H, t), 5.95(lH,br), 6.89 (2H, s) , 6.99-7.47 (llH,m), 7.94-7.97 (1H, m) 2.68 (2H, t), 2.66-2.76 (2Η, ι), 4.32 (2H, t), 5.95 (lH, br), 6.89 (2H, s), 6.99-7.47 (llH, m), 7.94-7.97 ( 1H, m)
«例 3 «Example 3
2- [2- [4- (5H-ジベンゾ [a, d]シクロヘプテン- 5-ィリデン) -1-ビペリジニル]ェ トキシ] -N-(1H-テトラゾール -5-ィル)ベンズアミド 2- [2- [4- (5H-dibenzo [a, d] cycloheptene-5-ylidene) -1-biperidinyl] ethoxy] -N- (1H-tetrazol-5-yl) benzamide
例 2で得た 2-[2-[4-(5H-ジベンゾ [a, d]シクロヘプテン- 5-ィリデン )-1-ピ ペリジニル]エトキシ]ベンゾィヅクァシヅド 200mg (0.46腿 ol) を無 ジメチル ホルムァミト' 5mlに溶解し、 Ι, -カルポジイミダゾール 185mg (1.14腿 ol) を 加えて、 80。Cで 2時間 した。冷後、 5-アミノテトラゾール 142mg (1.37匪 ol) を加えて、 80でで 2時間撹拌した。 冷後、 液に水を加えて析出した結晶をろ 取し、標記化合物 167mgを得た。収率 73%。
ァモノレファス 200 mg (0.46 tmol) of 2- [2- [4- (5H-dibenzo [a, d] cycloheptene-5-ylidene) -1-piperidinyl] ethoxy] benzodiacid obtained in Example 2 was used. Dissolve in 5 ml of dimethylformamide, add 185, -carpoimidazole 185 mg (1.14 t ol), and add 80. C for 2 hours. After cooling, 142 mg (1.37 marl) of 5-aminotetrazole was added, and the mixture was stirred at 80 for 2 hours. After cooling, water was added to the solution, and the precipitated crystals were collected by filtration to obtain 167 mg of the title compound. 73% yield. Amonorefass
MS i /z) : 504 (M+) MS i / z): 504 (M + )
IR (nujol) cm-1: 1670 IR (nujol) cm -1 : 1670
麵 (CDCla) δ : 2. 13-2. 20 (2Η, m), 2. 27-2. 45 (4H, m), 2. 75-2. 85 (2H, m) , CD (CDCla) δ: 2.13-2.20 (2Η, m), 2.27-2.45 (4H, m), 2.75-2.85 (2H, m),
2. 89 (2H, t) , 3. 00-3. 60 (2H, br) , 4. 37 (2H, t) , 6. 89 (2H, s) , 7. 02 - 7. 36 (10H, m) , 7. 52-7. 59 (1H, m) , 8. 14 (1¾ dd) 2.89 (2H, t), 3.00-3.60 (2H, br), 4.37 (2H, t), 6.89 (2H, s), 7.02-7.36 (10H, m), 7.52-7.59 (1H, m), 8.14 (1¾ dd)
鋪例 4〜15 Shop example 4-15
m i〜 3の方法に準拠して表 3〜 5に示す実施例 4〜 15の化合物を得た。 各々の化 名は以下の通りである。表中、 A、 B、 R、 m及び Xは本発明化合 物(I)中の記号を表す。なお、 表中 X基の欄において は A環との結合を表す。 麵例 4 The compounds of Examples 4 to 15 shown in Tables 3 to 5 were obtained according to the methods of mi to 3. Each chemical name is as follows. In the table, A, B, R, m and X represent symbols in the compound (I) of the present invention. In addition, in the column of the X group in the table, it represents a bond with the A ring.麵 Example 4
2- [2- [4- (10-ォキソ -9, 10-ジヒドロ- 4H-ベンゾ [4, 5]シクロへブタ [1, 2-b]チォ フェン- II-ィリデン) -1-ピペリジニル]エトキシ]ペンゾィヅクァシヅドメチルェ ステル 2- [2- [4- (10-oxo-9,10-dihydro-4H-benzo [4,5] cyclohepta [1,2-b] thiophene-II-ylidene) -1-piperidinyl] ethoxy ] Penzoic methyl ester
例 5 Example 5
2- [2- [4- (10-ォキソ -9, 10-ジヒドロ- 4H-ペンゾ [4, 5]シクロへプタ [1, 2-b]チォ フェン- 11-ィリデン) -1-ビペリジニル]エトキシ]ペンゾィヅクァシヅド 2- [2- [4- (10-oxo-9,10-dihydro-4H-benzo [4,5] cyclohepta [1,2-b] thiophen-11-ylidene) -1-biperidinyl] ethoxy ] Penzoic Quasid
mmm 6 mmm 6
2- [2- [4- (10-ォキソ -9, 10-ジヒド口- 4H-ペンゾ [4, 5]シクロへブタ [1, 2-b]チォ フェン -11-ィリデン) -1-ビぺリジニル]ェトキシ] -N- (1H-テトラゾール -5-ィル) ペンズアミド 2- [2- [4- (10-oxo-9,10-dihydropent-4H-benzo [4,5] cyclohepta [1,2-b] thiophen-11-ylidene) -1-bi ぺLysinyl] ethoxy] -N- (1H-tetrazol-5-yl) penzamide
雄例 7 Male example 7
2- [3- [4- (10-ォキソ -9, 10-ジヒドロ- 4H-ベンゾ [4, 5]シク口ヘプ夕 [1, 2-b]チォ フェン- 11-イリデン) -1-ビペリジニル]プロボキシ]ペンゾィヅクァシヅドメチル エステル 2- [3- [4- (10-oxo-9,10-dihydro-4H-benzo [4,5] cyclohexyl [1,2-b] thiophen-11-ylidene) -1-biperidinyl] Proboxy] benzoic acid methyl ester
魏例 8 Wei example 8
2- [3- [4- (10-ォキゾ -9, 10-ジヒドロ- 4K-ベンゾ [4, 5]シクロヘプ夕 [1, 2-b]チォ フェン- 11-イリデン) -1-ビペリジニル]プロボキシ]ペンゾィヅクァシヅド 2- [3- [4- (10-oxo-9,10-dihydro-4K-benzo [4,5] cyclohepno [1,2-b] thiophen-11-ylidene) -1-biperidinyl] propoxy] Penzo Quasid
麵例 9
2- [3- [4- (10-ォキソ -9, 10-ジヒド口- 4H-ベンゾ [4, 5]シクロヘプ夕 [1, 2-b]チォ フェン- 1卜ィリデン) -1-ビペリジニル]プロポキシ] -N- (1H-テトラゾール -5-ィル) ベンズアミド 麵 Example 9 2- [3- [4- (10-oxo-9,10-dihydropent-4H-benzo [4,5] cyclohepno [1,2-b] thiophen-1 trilidene) -1-biperidinyl] propoxy ] -N- (1H-tetrazol-5-yl) benzamide
2- [2- [4- (8-クロ口 -5, 6-ジヒドロ- 11H-ベンゾ [5, 6]シクロヘプ夕 [1, 2-b]ビリ ジン- 11-ィリデン ) -1-ピペリジニル]エトキシ]ベンゾイツクァシヅドメチルエス テル 2- [2- [4- (8-Chloro-5,6-dihydro-11H-benzo [5,6] cycloheptane [1,2-b] Vyridin-11-ylidene) -1-piperidinyl] ethoxy ] Benzoic acid methyl ester
魏例 11 Wei example 11
2 - [2- [4- (8-クロ口 -5, 6-ジヒドロ- 11H-ベンゾ [5, 6]シク口へブ夕 [1, 2-b]ビリ ジン- U-ィリデン) -卜ビペリジニル]エトキシ]ベンゾィヅクァシヅド 2- [2- [4- (8-chloro-5,6-dihydro-11H-benzo [5,6] cyclohexyl [1,2-b] viridine-U-ylidene) -toviperidinyl ] Ethoxy] benzoic acid
餓例 12 Hunger 12
2- [2- [4- (8-クロ口- 5, 6-ジヒドロ- 11H-ベンゾ [5, 6]シク口へブタ [1, 2-b]ビリ ジン- 1卜ィリデン) -卜ビベリジニル]エトキシ] -N- (1H-テトラゾール -5-ィル)ベ ンズァミド 2- [2- [4- (8-chloro-5,6-dihydro-11H-benzo [5,6] cyclobuta] [1,2-b] Biridine-1 trilidene) -toviberidinyl] Ethoxy] -N- (1H-tetrazol-5-yl) benzamide
鋪例 13 Shop example 13
2- [2- [4- (10, 11-ジヒド口 -5H-ジベンゾ [a, d]シク口ヘプテン- 5-ィリデン) -1- ビペリジニル]エトキシ]ベンゾィヅクァシヅドメチルエステル 2- [2- [4- (10,11-dihydroxy-5H-dibenzo [a, d] cycloheptene-5-ylidene) -1-biperidinyl] ethoxy] benzodiacid methyl ester
赚例 14 赚 Example 14
2- [2- [4- (10, 11-ジヒドロ- 5H-ジベンゾ [a, d]シクロヘプテン- 5-ィリデン)-1- 謹例 15 2- [2- [4- (10,11-Dihydro-5H-dibenzo [a, d] cycloheptene-5-ylidene) -1- Discreet Example 15
2- [2- [4- (10, 11-ジヒドロ- 5H-ジベンゾ [a, d]シクロヘプテン- 5-ィリデン)-1- ピペリジニル]エトキシ] -N- (1H-テトラゾール -5-ィル)ベンズアミド
表 4 2- [2- [4- (10,11-dihydro-5H-dibenzo [a, d] cycloheptene-5-ylidene) -1-piperidinyl] ethoxy] -N- (1H-tetrazol-5-yl) benzamide Table 4
»例 1の化^/ 50g »Example 1 ^ / 50g
315g 315g
トウモロコシデンプン 125g 125g corn starch
結晶セルロース 25g 25g crystalline cellulose
上記成分を均一に混合し、 7. 5%ヒドロキシプロピルセルロース水溶液 200 を加え、 押出し造粒機により、 直径 0. 5 スクリーンを用いて顆粒とし、 直ちに マルメライザ一により丸めた後、 乾燥し顆粒剤とした。 The above components are mixed uniformly, and a 200% aqueous solution of 7.5% hydroxypropylcellulose is added, and the mixture is granulated by an extrusion granulator using a screen with a diameter of 0.5, immediately rounded with a marmellaizer, and dried to obtain granules. did.
この乾^^粒剤に下記 のフィルムコ一ティング液 1. 9kgを流動層 機を 用いてコーティングし、 腸溶 ½^粒剤とした。 The dry granules were coated with 1.9 kg of the following film coating solution using a fluidized bed machine to obtain enteric coated granules.
コーティング Coating
ヒドロキシプロビルメチルセルロースフタレート 5. 0 ( /w) % Hydroxypropyl methylcellulose phthalate 5.0 (/ w)%
ステアリン酸 0. 25 (w/w) % Stearic acid 0.25 (w / w)%
塩ィ匕メチレン 50. 0 (w/w) % Shiodii Methylene 50.0 (w / w)%
エタノール 44. 75 (w/w) % 製剤例 2 Ethanol 44.75 (w / w)% Formulation Example 2
«例 5の化^/ 20g «Example 5: ^ / 20g
乳糖 100g Lactose 100g
トウモロコシデンプン 36g 36g corn starch
結晶セルロース 30g 30g crystalline cellulose
カルボキシメチルセルロースカルシウム 10g Carboxymethylcellulose calcium 10g
ステアリン酸マグネシウム 4g Magnesium stearate 4g
上記ま! ^の成分を均一に混合し、 単発打 I»にて直径 7. 5nmの杵で 1錠 200ngの ,とした。 Above! The components of ^ were uniformly mixed and made into 200 ng per tablet with a single punch I »with a 7.5 nm diameter punch.
次いで、 この錠剤に下記組成のコーティング液をスプレーコーティングして 1 錠当り lOngの被覆を施し、 腸溶性フィルムコーティング^ 0とした。 Next, the tablet was spray-coated with a coating solution having the following composition to give a coating of 100 ng per tablet, thereby obtaining an enteric film coating ^ 0.
コーティング γ¾ίΜ: Coating γ¾ίΜ:
ヒドロキシプロビルメチルセルロースフタレート 8. 0 (w/w) % Hydroxypropyl methylcellulose phthalate 8.0 (w / w)%
グリセリン脂肪酸エステル 0. 4 (w/w) %
塩化メチレン 50. 0 (w/w) % Glycerin fatty acid ester 0.4 (w / w)% Methylene chloride 50.0 (w / w)%
サラシミヅロウ 0. 1 (w/w) % Sara Shimizu wax 0.1 (w / w)%
ィソブロピルアルコール 41. 5 ( /w) % Isopropropyl alcohol 41.5 (/ w)%
觀例 3 Observation example 3
贿例 15の化^ i 0. 1 (w/ff) % 化 Example 15: ^ i 0.1 (w / ff)%
エタノール 20. 0 ( /w) % Ethanol 20.0 (/ w)%
液化ガス (プロペラント 114) 49. 2 (w/w) % Liquefied gas (propellant 114) 49.2 (w / w)%
液化ガス (プロペラント 12) 30. 7 (w/w) % Liquefied gas (Propellant 12) 30.7 (w / w)%
上 ,方で常法によりエアゾール剤とした。 Above, the aerosol was prepared by the usual method.
:の利用可難 : Difficult to use
J¾±のように、本発明の化^/は強い抗ヒスタミン作用を示し、 かつ安全性も 高いことから、 各種アレルギ H¾患、 例えば抗炎症剤、 腎炎、肝炎、脬炎等の mk 呼吸器疾患の予防及び/又は治 並びに抗喘息薬として有用である。
As shown in J¾ ±, the compound of the present invention exhibits strong antihistamine activity and high safety. It is useful as a prophylactic and / or curative drug and as an anti-asthmatic drug.
Claims
請求の範囲 The scope of the claims
. 一般式(I ) General formula (I)
(式中、 Rは水素原子又はハロゲン原子を示し、 Xは基—CH2CH2—、 一 CH=CH—又は一 CH2— CO—を示し、 Aはベンゼン環、 チォフェン 環又はピリジン環を示し、 Bはヒドロキシル基、 低級アルコキシル基又は 基 を示し、 mは 2〜5の整数を示す。 )(In the formula, R represents a hydrogen atom or a halogen atom, X represents a group —CH 2 CH 2 —, one CH = CH— or one CH 2 —CO—, and A represents a benzene ring, a thiophene ring, or a pyridine ring. And B represents a hydroxyl group, a lower alkoxyl group or a group, and m represents an integer of 2 to 5.)
で表される三 TO化 0 Three TOs represented by 0
2. 請求項 1記載のジフエニルメトキシピペリジン誘導体を有効成分とする抗ヒ スタミン剤。 2. An antihistamine comprising the diphenylmethoxypiperidine derivative according to claim 1 as an active ingredient.
3. 請求項 1記載のジフエニルメトキシビペリジン誘導体を有効成分とする抗ァ レルギ一剤。 3. An anti-allergic agent comprising the diphenylmethoxybiperidine derivative according to claim 1 as an active ingredient.
4. 抗喘息薬である請求項 3記載の抗アレルギ U。
4. The anti-allergic U according to claim 3, which is an anti-asthmatic drug.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3/356615 | 1991-12-25 | ||
JP35661591 | 1991-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993013068A1 true WO1993013068A1 (en) | 1993-07-08 |
Family
ID=18449913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/001640 WO1993013068A1 (en) | 1991-12-25 | 1992-12-16 | Tricyclic compound and medicine containing the same |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3170793A (en) |
WO (1) | WO1993013068A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014526438A (en) * | 2011-06-28 | 2014-10-06 | フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド | Anti-allergic benzocycloheptathiophene derivatives |
CN107602534A (en) * | 2017-09-05 | 2018-01-19 | 合肥医工医药有限公司 | Compound with antihistamine and anti-inflammatory activity and its preparation method and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012443A1 (en) * | 1988-06-17 | 1989-12-28 | Fisons Corporation | Novel dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties |
JPH0347168A (en) * | 1988-11-30 | 1991-02-28 | Ajinomoto Co Inc | Piperidine derivative and hypotensor containing same derivative |
JPH0363263A (en) * | 1989-05-19 | 1991-03-19 | Hoechst Roussel Pharmaceut Inc | N-(aryloxyalkyl)heteroarylpiperidine and N-(aryloxyalkyl)heteroarylpiperazine |
-
1992
- 1992-12-16 WO PCT/JP1992/001640 patent/WO1993013068A1/en active Application Filing
- 1992-12-16 AU AU31707/93A patent/AU3170793A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012443A1 (en) * | 1988-06-17 | 1989-12-28 | Fisons Corporation | Novel dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties |
JPH0347168A (en) * | 1988-11-30 | 1991-02-28 | Ajinomoto Co Inc | Piperidine derivative and hypotensor containing same derivative |
JPH0363263A (en) * | 1989-05-19 | 1991-03-19 | Hoechst Roussel Pharmaceut Inc | N-(aryloxyalkyl)heteroarylpiperidine and N-(aryloxyalkyl)heteroarylpiperazine |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014526438A (en) * | 2011-06-28 | 2014-10-06 | フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド | Anti-allergic benzocycloheptathiophene derivatives |
CN107602534A (en) * | 2017-09-05 | 2018-01-19 | 合肥医工医药有限公司 | Compound with antihistamine and anti-inflammatory activity and its preparation method and application |
CN107602534B (en) * | 2017-09-05 | 2020-04-24 | 合肥医工医药股份有限公司 | Compound with anti-histamine and anti-inflammatory activity and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU3170793A (en) | 1993-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2167152C2 (en) | N-substituted azaheterocyclic carboxylic acids or their pharmaceutically acceptable salts, method of their synthesis, pharmaceutical composition based on thereof and method of inhibition of neurogenic inflammation | |
US4929621A (en) | 1-1[(2-pyrimidinyl)amino-alkyl]piperidines, their preparation and their application in therapy | |
US6054458A (en) | Heterocyclic compounds | |
EP0991621A1 (en) | Novel heterocyclic compounds | |
JPH0568476B2 (en) | ||
CS247094B2 (en) | Preparation method of 5,11-dihydro-11-(((methyl-4-piperidinyl)amino)carbonyl)-6h-dibenz(b,e)-azepin-6-on | |
DD207377A5 (en) | PROCESS FOR THE PREPARATION OF NEW THEOPHYLLINE DERIVATIVES | |
WO1993002062A1 (en) | Piperazine derivative and drug containing the same | |
JPS58219166A (en) | 4-quinolone derivative | |
JP2001501937A (en) | N-substituted azaheterocyclic compounds | |
US4853387A (en) | Piperidine derivatives, and their application in therapy | |
AU698673B2 (en) | Heterocyclic chemistry | |
WO1993013068A1 (en) | Tricyclic compound and medicine containing the same | |
JPS6143183A (en) | Novel 2h-1-benzopyran-2-one derivative, manufacture and antiallergic disease remedy | |
JPH04234359A (en) | New derivatives of 1-diphenylmethylpiperazine, process for producing same and use thereof as medicines | |
JP3499569B2 (en) | New heterocyclic compounds | |
JPS647995B2 (en) | ||
JPS62212386A (en) | 2-pyridylmethylbenzimidazole derivative | |
JP2001501628A (en) | N-substituted azaheterocyclic compounds | |
US5827856A (en) | Method of treating insulin resistance | |
JP2676170B2 (en) | Bicyclolactam derivative | |
JPH0680041B2 (en) | 2-Pyridylacetic acid derivative, method for producing the same, and medicament containing the same | |
JPH01242574A (en) | Piperidine and piperazine derivatives having a nitrogen-containing condensed ring, methods for producing the same, and pharmaceutical compositions containing the same | |
JPH11503128A (en) | New heterocyclic compounds | |
US5106859A (en) | Certain 1,3,4-thiadiazole derivatives and anti-ulcer agent comprising said derivatives as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR RU UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |